Every 10-Q that Surgery Partners, Inc. (SGRY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SGRY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGRY filings page.
Surgery Partners, Inc. operates 178 surgical facilities across 30 states and reported modest top-line growth but continued losses attributable to common shareholders for the quarter ended June 30, 2026. Second‑quarter revenues were $848.9 million, up from $826.2 million a year earlier, driven by 5.0% growth in days adjusted same‑facility revenues, with a 4.8% increase in revenue per case and a 0.3% rise in same‑facility case volumes.
Cost pressures offset this growth. Cost of revenues rose to $658.7 million, 77.6% of revenues versus 76.3% last year, reflecting higher case volume, more high‑acuity procedures and increased provider taxes. Operating income declined to $102.1 million from $111.7 million, while interest expense, net, was $69.8 million, leaving income before taxes of $32.3 million. After taxes and significant earnings attributable to non‑controlling interests, net loss attributable to Surgery Partners, Inc. widened to $15.0 million versus $2.5 million.
For the first half of 2026, revenues were $1,659.8 million and Adjusted EBITDA was $227.5 million. The company held $216.7 million of cash and had $617.8 million of revolver availability, alongside $3,751.2 million of total debt. A subsequent‑events note discloses signed agreements to sell controlling interests in two hospitals for approximately $795 million of total consideration, including amounts tied to associated debt.
Surgery Partners reported Q1 2026 revenue of $810.9 million, up from $776.0 million a year earlier, driven by a 4.4% rise in days adjusted same-facility revenue, with 3.8% higher revenue per case and 0.6% higher case volumes.
Net loss attributable to Surgery Partners, Inc. was $35.9 million versus $37.7 million in Q1 2025, while Adjusted EBITDA edged down to $102.3 million from $103.9 million as higher cost of revenues and interest expense offset topline growth.
The company ended the quarter with $182.3 million of cash and $666.1 million of availability on its senior secured revolver, against total debt of about $3.7 billion. The board also authorized a new share repurchase program of up to $200 million of common stock, with no repurchases made in the quarter.
Surgery Partners, Inc. (SGRY) reported higher revenue and improved operating performance in Q3 2025. Revenue rose to $821.5 million from $770.4 million, driven by same‑facility growth and recent portfolio actions. Operating income increased to $105.7 million from $60.9 million as salaries, supplies, and professional fees scaled with volume. Net loss attributable to Surgery Partners narrowed to $22.7 million from $31.7 million as interest expense remained elevated at $74.9 million.
Management highlighted days‑adjusted same‑facility revenue up 6.3% year over year, with a 2.8% increase in revenue per case and a 3.4% lift in same‑facility cases. For the nine months, revenue reached $2,423.7 million versus $2,249.9 million, while the net loss attributable to the company was $62.9 million.
Liquidity and capital structure shifted following an August refinancing. The company entered into $1,383 million of 2025 Refinancing Term Loans maturing in 2030 at Term SOFR plus 2.50% (or an alternate base rate plus 1.50%) and extended revolving commitments to 2028. Cash and cash equivalents were $203.4 million, with $405.9 million of availability on the $703.8 million revolver. Total debt was $3,563.6 million, including $800.0 million of 7.250% senior notes due 2032. As of November 3, 2025, common shares outstanding were 129,341,779.